mercaptopurine


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

mer·cap·to·pu·rine

 (mər-kăp′tō-pyo͝or′ēn)
n.
A purine analog, C5H4N4S, that interferes with the synthesis of purines and is used primarily in the treatment of certain forms of leukemia.

mercaptopurine

(məˌkæptəʊˈpjʊəriːn)
n
(Pharmacology) a drug used in the treatment of leukaemia. Formula: C5H4N4S
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.mercaptopurine - a drug (trade name Purinethol) that interferes with the metabolism of purine and is used to treat acute lymphocytic leukemia
antimetabolite - an antineoplastic drug that inhibits the utilization of a metabolite
References in periodicals archive ?
Moreover, trans effects of single-nucleotide polymorphisms that affect TPMT activity and mercaptopurine sensitivity have recently been discovered in the PACSIN2 (protein kinase C and casein kinase substrate in neurons 2) gene.
13,15) Recently, mercaptopurine has been also implicated in inducing a secondary malignancy.
Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.
In addition, the injection of Tp (inducer of [alpha]2M production) into infected rats led to an increased parasitaemia that reached its peak on the seventh day post-treatment (19% [+ or -] SD), while inhibition of [alpha]2M production by mercaptopurine reduced the parasitaemia to 2-3% [+ or -] SD in the SI rats and to 23% [+ or -] SD in the CyI rats (Fig.
golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Fourteen patients (aged 16-80 years; mean, 49 years) with mild-to-moderate ulcerative colitis (n = 10) or Crohn's disease colitis with no known small-intestinal Crohn's disease (n = 4), who were receiving stable therapy with oral aminosalicylates, mercaptopurine, or azathioprine for at least 8 weeks were treated with 1 g of orally administered colon-release propionyl-L-carnitine hydrochloride twice a day (1 hour before breakfast and 1 hour before dinner) for 4 weeks.
Background & objectives: Mercaptopurine, azathioprine, and thioguanine, used as antineoplastic agents and immunosuppressants are catabolized by thiopurine methyltransferase (TPMT) enzyme, which exhibits genetic polymorphism.
However, febuxostat is contraindicated in patients who are taking azathioprine, mercaptopurine, and theophylline.
In addition to the anabolic pathway, 6-MP is catabolized to 6-thiouric acid by xanthine oxidase and to 6-methyl mercaptopurine (6-MMP) by thiopurine S-methyltransferase (TPMT) (8).
Patients with the NUDT15 variant required a mercaptopurine dose reduction of as much as 92 percent.
Preponderance of thiopurine Smethyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Mercaptopurine: Methotrexate increases the plasma levels of mercaptopurine, therefore dose adjustment may be required.